Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TTK | P33981 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | TXK | P42681 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | ITK | Q08881 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30925312 | 1.00 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL30225760 | 1.00 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209829 | 0.94 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209789 | 0.93 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209883 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209823 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209776 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209790 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209896 | 0.91 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209797 | 0.91 | JAK3 (0.86) | JAK3JAK2EGFRJAK1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-112804994-A | Method for treating myeloproliferative tumors | 卡托斯医疗公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-3801476-A2 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164614-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015164614-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044111-A1 | JANUS KINASE INHIBITORS AND USES THEREOF | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885EGFR 692/4885 |
| US-10017477-B2 | Janus kinase inhibitors and uses thereof | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885EGFR 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.